Mayukh Sukhatme sold $9.0M of ROIV
President & CIO at Roivant Sciences Ltd.. 339,441 shares at an average of $26.47, traded Feb 9, 2026, filed Feb 11, 2026.
Score components
- +20RolePresident
- +25Trade size$9.0M at market
- 0Share of holdings soldSold 1.7% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.7%, 3m +9.0%, 6m +34.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001635088-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | MOption exercise Common Shares | +651,558 | $12.68 | $8.3M | 19,488,105 | Feb 11, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Shares | -339,441 | $26.47 | $9.0M | 19,148,664 | Feb 11, 2026 |
| Feb 9, 2026 | JOther Common Shares | -312,117 | $26.47 | $8.3M | 18,836,547 | Feb 11, 2026 |
| Feb 9, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -651,558 | $0.00 | $0 | 0 | Feb 11, 2026 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 35Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 38Weak | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $12M 335,174 shares | -2% | |
| 38Weak | Roivant Sciences Ltd. | Mayukh Sukhatme President & CIO | $24M 664,826 shares | -4% | |
| 20Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.0M 200,000 shares | -11% | |
| 15Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $349k 10,000 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.